The Effect of Hormonal Contraception and Menstrual Cycle Timing on Genital Herpes Simplex Virus-2 Shedding and Lesions.


Journal

Sexually transmitted diseases
ISSN: 1537-4521
Titre abrégé: Sex Transm Dis
Pays: United States
ID NLM: 7705941

Informations de publication

Date de publication:
01 2019
Historique:
pubmed: 28 8 2018
medline: 26 2 2020
entrez: 28 8 2018
Statut: ppublish

Résumé

The effect of female sex hormones on herpes simplex virus (HSV)-2 shedding and lesion frequency is poorly understood. Previous studies suggest that hormonal contraception may increase the frequency of HSV-2 shedding. We studied HSV-2 seropositive women who performed daily genital swabbing for HSV DNA and completed diaries for genital lesions and menses. We used Poisson mixed effects models to determine if HSV detection varied throughout the menstrual cycle, or in response to hormonal contraception. We used the Wilcoxon signed-rank test and rank-sum test to determine if lesion frequency differed by cycle phase or hormonal contraceptive use. In 189 women aged 19 to 46 years who collected swabs on 10,715 days and were not using hormonal contraception, HSV-2 DNA was detected on 20.9% of days in the follicular phase and 17.8% of days in the luteal phase (rate ratio, 1.19; 95% confidence interval, 1.03-1.37, P = 0.02). Genital lesions did not differ in the follicular versus luteal phase (12.8% vs. 10.7%, P = 0.07). In analyses of hormonal contraception, including 244 women, HSV-2 DNA was detected on 19.0% of days for women not using hormonal contraception and 18.3% of days for those using hormonal contraception (P = 0.50). Lesions were present on 11.1% of days for women not using hormonal contraception, and 8.7% of days for those using hormonal contraception (P = 0.66). In women with genital HSV-2 infection who are not using hormonal contraception, the follicular phase of the cycle may be associated with a higher frequency of HSV-2 shedding compared to the luteal phase. Lesion frequency is similar during the 2 menstrual phases. Hormonal contraception use was not observed to affect genital HSV-2 DNA detection or lesions.

Sections du résumé

BACKGROUND
The effect of female sex hormones on herpes simplex virus (HSV)-2 shedding and lesion frequency is poorly understood. Previous studies suggest that hormonal contraception may increase the frequency of HSV-2 shedding.
METHODS
We studied HSV-2 seropositive women who performed daily genital swabbing for HSV DNA and completed diaries for genital lesions and menses. We used Poisson mixed effects models to determine if HSV detection varied throughout the menstrual cycle, or in response to hormonal contraception. We used the Wilcoxon signed-rank test and rank-sum test to determine if lesion frequency differed by cycle phase or hormonal contraceptive use.
RESULTS
In 189 women aged 19 to 46 years who collected swabs on 10,715 days and were not using hormonal contraception, HSV-2 DNA was detected on 20.9% of days in the follicular phase and 17.8% of days in the luteal phase (rate ratio, 1.19; 95% confidence interval, 1.03-1.37, P = 0.02). Genital lesions did not differ in the follicular versus luteal phase (12.8% vs. 10.7%, P = 0.07). In analyses of hormonal contraception, including 244 women, HSV-2 DNA was detected on 19.0% of days for women not using hormonal contraception and 18.3% of days for those using hormonal contraception (P = 0.50). Lesions were present on 11.1% of days for women not using hormonal contraception, and 8.7% of days for those using hormonal contraception (P = 0.66).
CONCLUSIONS
In women with genital HSV-2 infection who are not using hormonal contraception, the follicular phase of the cycle may be associated with a higher frequency of HSV-2 shedding compared to the luteal phase. Lesion frequency is similar during the 2 menstrual phases. Hormonal contraception use was not observed to affect genital HSV-2 DNA detection or lesions.

Identifiants

pubmed: 30148758
doi: 10.1097/OLQ.0000000000000907
pmc: PMC6289656
mid: NIHMS1504437
doi:

Substances chimiques

DNA, Viral 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

58-62

Subventions

Organisme : NICHD NIH HHS
ID : K12 HD001264
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI030731
Pays : United States

Références

J Virol. 2015 Sep;89(17):8793-805
pubmed: 26085144
PLoS One. 2012;7(8):e43951
pubmed: 22952818
AIDS Res Hum Retroviruses. 2016 Jun;32(6):547-60
pubmed: 26750085
Mucosal Immunol. 2016 Nov;9(6):1571-1583
pubmed: 27007679
N Engl J Med. 1999 Nov 4;341(19):1432-8
pubmed: 10547406
J Infect Dis. 2003 Nov 1;188(9):1345-51
pubmed: 14593592
Lancet Glob Health. 2017 Mar;5(3):e300-e309
pubmed: 28153513
Contraception. 2018 Jan;97(1):14-21
pubmed: 29038071
Nat Rev Immunol. 2015 Apr;15(4):217-30
pubmed: 25743222
N Engl J Med. 2000 Mar 23;342(12):844-50
pubmed: 10727588
J Infect Dis. 2013 May 15;207(10):1616-20
pubmed: 23417658
AIDS. 2007 Feb 19;21(4):467-76
pubmed: 17301565
Am J Phys Anthropol. 2009;140 Suppl 49:95-136
pubmed: 19890865
Lancet. 2001 Apr 14;357(9263):1149-53
pubmed: 11323041
JAMA. 1990 Jan 19;263(3):418-20
pubmed: 2152951
Am J Reprod Immunol. 2012 Sep;68(3):244-50
pubmed: 22672628
J Infect Dis. 2011 Jan 15;203(2):180-7
pubmed: 21288817
Am J Obstet Gynecol. 2000 Oct;183(4):948-55
pubmed: 11035345
Lancet Glob Health. 2015 Aug;3(8):e478-e486
pubmed: 26094162
Clin Microbiol Rev. 2016 Jan;29(1):149-61
pubmed: 26561565
J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):359-66
pubmed: 26914908
Clin Infect Dis. 2005 May 15;40(10):1422-8
pubmed: 15844064
N Engl J Med. 1981 Mar 26;304(13):759-63
pubmed: 6258073
Sex Transm Infect. 2017 Jun;93(4):284-289
pubmed: 27821613
JAMA. 2011 Apr 13;305(14):1441-9
pubmed: 21486977
J Clin Microbiol. 1988 Apr;26(4):662-7
pubmed: 2835389
Ann Intern Med. 1996 Jan 1;124(1 Pt 1):8-15
pubmed: 7503497
J Clin Microbiol. 2002 Jul;40(7):2609-11
pubmed: 12089286
Lancet Infect Dis. 2017 Dec;17(12):1303-1316
pubmed: 28843576
Ann Intern Med. 1992 Feb 1;116(3):197-202
pubmed: 1309413
Sex Transm Infect. 2008 Oct;84 Suppl 2:ii12-8
pubmed: 18799486
MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137
pubmed: 26042815

Auteurs

Elizabeth Micks (E)

From the Department of Obstetrics and Gynecology.

Hyunju Son (H)

Department of Biostatistics.

Stacy Selke (S)

Department of Laboratory Medicine.

Christine Johnston (C)

Department of Medicine, and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH